Rhythm Pharmaceuticals (RYTM) AI Stock Analysis
Rhythm Pharmaceuticals
(BMV:RYTM)
No summary available
Rhythm Pharmaceuticals (RYTM) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- MXN 7.85B
- Dividend Yield
- ―
- Average Volume (3M)
- ―
- Price to Earnings (P/E)
- -39.3
- Beta (1Y)
- 0.47
- Revenue Growth
- 44.65%
- EPS Growth
- 15.73%
- Country
- Mexico
- Employees
- 414
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Rhythm Pharmaceuticals Business Overview & Revenue Model
Company Description
Rhythm Pharmaceuticals, Inc. is a biopharmaceutical company with commercial products, dedicated to the discovery, development, and market launch of therapies addressing rare genetic conditions that cause obesity. Its leading pharmaceutical, IMCIVREE,...
Rhythm Pharmaceuticals Earnings Call Summary
The call was strongly positive, led by 29% sequential revenue growth, a solid U.S. acquired HO launch, improving payer coverage, strong prescriber and reimbursed-patient trends, the Japan launch, and progress toward phase III studies in acquired HO and Prader-Willi syndrome. The company also reported substantial liquidity and expanded financing flexibility. Offsetting factors included a GAAP loss, higher R&D spending, the operational limitation of Japan's two-week prescription supply during its first year, ongoing physician-education and diagnosis work, and significant payments associated with the LG Chem amendment. Highlights significantly outweighed the lowlights.
Q3-2026 Updates
Positive Updates
Negative Updates
Company Guidance
Rhythm anticipates approximately $360 million-$380 million in non-GAAP operating expenses for 2026, comprised of non-GAAP R&D of $165 million-$175 million and non-GAAP SG&A of $195 million-$205 million; approximately $321 million in cash equivalents and short-term investments is expected to be sufficient to fund planned operations for at least 24 months. The company hopes to begin screening patients at the first sites for its 52-week bivamelagon HO study by the end of the year and expects to dose the first patients in January, with a six-month phase III PWS study targeted for 2027. In Japan, prescriptions are limited to a two-week supply during the first year, the restriction is expected to be lifted in November 2027, eligible patients may then receive prescription supply for up to three months, and the company anticipates a greater commercial contribution from Japan in the second and third years of launch; country-level acquired HO launches in Europe are expected during 2027, beginning with Germany.
Rhythm Pharmaceuticals Risk Analysis
Rhythm Pharmaceuticals disclosed 69 risk factors in its most recent earnings report. Rhythm Pharmaceuticals reported the most risks in the "Tech & Innovation" category.
Latest Risks Added
0 New RisksRhythm Pharmaceuticals Peers Comparison
Overall Rating
MBX47Neutral
QURE46Neutral
GPCR42Neutral
VKTX42Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| MBX | 47Neutral | $2.47B | -17.67 | -26.01% | ― | ― | -4.40% |
| QURE | 46Neutral | $1.52B | -6.44 | -96.34% | ― | 28.04% | 19.12% |
| GPCR | 42Neutral | $1.45B | -5.49 | -16.91% | ― | ― | 1.47% |
| VKTX | 42Neutral | $3.42B | -5.37 | -117.35% | ― | ― | -155.21% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| MX:RYTM | Rhythm Pharmaceuticals | 1860.00 | -165.00 | -8.15% | |
| QURE | uniQure N.V. | 21.70 | -9.14 | -29.64% | |
| VKTX | Viking Therapeutics | 26.84 | -13.76 | -33.89% | |
| GPCR | Structure Therapeutics, Inc. Sponsored ADR | 20.35 | -14.51 | -41.62% | |
| MBX | MBX Biosciences, Inc. | 51.35 | 26.44 | 106.14% | |
| KLRA | Kailera Therapeutics, Inc. | 12.97 | -13.03 | -50.12% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.